within Pharmacolibrary.Drugs.ATC.B;

model B02BD13
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.7 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,
    adminCount     = 1,
    Vd             = 4.9000000000000005e-05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Coagulation factor X is a vitamin K-dependent plasma glycoprotein produced in the liver that plays a key role in the coagulation cascade. Recombinant or plasma-derived factor X concentrates are used for the treatment and prevention of bleeding episodes in patients with hereditary factor X deficiency. Coagulation factor X replacement therapies are approved for use in individuals with this rare coagulation disorder.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported in adults with hereditary factor X deficiency after intravenous administration of plasma-derived factor X.</p><h4>References</h4><ol><li><p>Heo, YA (2018). Andexanet Alfa: First Global Approval. <i>Drugs</i> 78(10) 1049–1055. DOI:<a href=&quot;https://doi.org/10.1007/s40265-018-0940-4&quot;>10.1007/s40265-018-0940-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29926311/&quot;>https://pubmed.ncbi.nlm.nih.gov/29926311</a></p></li><li><p>Krutzke, L, et al., &amp; Kreppel, F (2016). Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 235 379–392. DOI:<a href=&quot;https://doi.org/10.1016/j.jconrel.2016.06.022&quot;>10.1016/j.jconrel.2016.06.022</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27302248/&quot;>https://pubmed.ncbi.nlm.nih.gov/27302248</a></p></li><li><p>Ishida, M, et al., &amp; Sakamoto, F (1998). Pharmacokinetics of danaparoid sodium, dalteparin sodium and heparin determined by inhibitory effect on the activated coagulation factor X activity after single intravenous administration in rabbits. <i>Arzneimittel-Forschung</i> 48(8) 818–821. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9748709/&quot;>https://pubmed.ncbi.nlm.nih.gov/9748709</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B02BD13;
